Inflammatory Biomarkers in Diffuse Large B-Cell Lymphoma: Time for Extending the Established Prognosis Scores?

Acta Haematologica

Volumn 137, Issue 2, 2017, Pages 73-75

  Posch, Florian ^a   Pichler, Martin ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; SERUM ALBUMIN; TUMOR MARKER;

BLOOD CELL COUNT; BODY MASS; CLINICAL OUTCOME; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LIVER FUNCTION; LYMPHOCYTE COUNT; MORTALITY; NEUTROPHIL LYMPHOCYTE RATIO; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; DIFFUSE LARGE B CELL LYMPHOMA; IMMUNOHISTOCHEMISTRY; PROGNOSIS;

BIOMARKERS; BIOMARKERS, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS;

EID: 85009375021     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000455020     Document Type: Note

References (8)

1. Al-Zoughbi W, Huang J, Paramasivan GS, Till H, Pichler M, Guertl-Lackner B, Hoefler G: Tumor macroenvironment and metabolism. Semin Oncol 2014; 41: 281-295.
2. Park YH, Yi HG, Lee MH, Kim CS, Lim JH: Prognostic value of the pretreatment advanced lung cancer inflammation index (ALI) in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy. Acta Haematol 2017;137:76-85.
3. Jafri SH, Shi R, Mills G: Advanced lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer 2013; 13: 158.
4. Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Trankenschuh W, Schlick K, Huemer F, Deutsch A, Neumeister P, Greil R, Pichler M, Egle A: Independent prognostic value of serum markers in diffuse large B-cell lymphoma in the era of the NCCN-IPI. J Natl Compr Cancer Netw 2015; 13: 1501-1508.
5. Konigsbrugge O, Posch F, Riedl J, Reitter EM, Zielinski C, Pabinger I, Ay C: Association between decreased serum albumin with risk of venous thromboembolism and mortality in cancer patients. Oncologist 2016; 21: 252-257.
6. Szkandera J, Pichler M, Gerger A, Leithner A: Reply: comment on "Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients." Br J Cancer 2013; 108: 2627.
7. Steyerberg EW, Vickers AJ: Decision curve analysis: a discussion. Med Decis Making 2008; 28: 146-149.
8. Fizazi K, Pagliaro L, Laplanche A, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S: Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 2014; 15: 1442-1450.